Adis Journals
DUR-TO-DE-002 PLS slide Final 6 Nov 2023.pdf (231.85 kB)

Durvalumab: A Review in Advanced Biliary Tract Cancer

Download (231.85 kB)
online resource
posted on 2023-11-09, 21:52 authored by Simon Fung, Yahiya Y. Syed

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest S. Fung and Y. Y. Syed are salaried employee of Adis International Ltd/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here


Durvalumab (Imfinzi®), a therapeutic human monoclonal antibody which binds to and blocks the activity of the immunosuppressive programmed death-ligand 1 (PD-L1) protein, is approved in the USA, EU, Japan and other countries in combination with gemcitabine and cisplatin for adults with advanced biliary tract cancer. In the pivotal phase 3 TOPAZ-1 trial, durvalumab plus gemcitabine and cisplatin significantly prolonged overall survival and progression-free survival compared with placebo plus gemcitabine and cisplatin in adults with advanced biliary tract cancer. Benefit from durvalumab was seen irrespective of primary tumour location, disease status at diagnosis (unresectable or recurrent), or initial levels of PD-L1 expression. The tolerability of durvalumab plus gemcitabine and cisplatin was manageable. Overall, the addition of durvalumab to gemcitabine and cisplatin is a valuable new treatment option for adults with advanced biliary tract cancer.

© Springer Nature Switzerland AG 2023


Usage metrics

    Targeted Oncology



    Ref. manager